Ruben Mesa, MD

Reflections on the predominant challenges one may face while making a differential diagnosis of myelofibrosis.

Shared insight on the differential diagnosis of myelofibrosis, including advice for identifying primary versus secondary disease.

A brief discussion on the role of ruxolitinib in the management of polycythemia vera, followed by a review of goals of therapy in this setting.

Pankit Vachhani, MD, provides a comprehensive overview of approved agents used to manage patients with polycythemia vera.

Ruben A. Mesa, MD, discusses various determinants of disparities in cancer care.

Shared insight on making a differential diagnosis of polycythemia vera and properly risk-stratifying patients who present with this disease.

Ruben A. Mesa, MD, discusses the importance of community engagement to facilitate optimal care in oncology.

Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.

Ruben A. Mesa, MD, discusses the unique characteristics of pacritinib in the treatment of patients with myelofibrosis.

Ruben A. Mesa, MD, discusses results seen with momelotinib in patients with transfusion-independent myelofibrosis, as demonstrated in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.

Ruben A. Mesa, MD, discusses the anticipated utility of momelotinib in myelofibrosis.

Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.

Ruben A. Mesa, MD, discusses emerging therapies in myelofibrosis.

Ruben A. Mesa, MD, discusses mitigating racial disparities in myeloproliferative neoplasm clinical trials.

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis and baseline thrombocytopenia.

Ruben Mesa, MD, discusses unanswered questions regarding JAK inhibitors in myelofibrosis.

Ruben Mesa, MD, discusses remaining challenges in treating myelofibrosis.

Ruben Mesa, MD, discusses therapiesunder investigation in myelofibrosis.

Ruben Mesa, MD, discusses the utility of fedratinib for patients with myelofibrosis who progress on first-line ruxolitinib.

Ruben Mesa, MD, discusses the challenges with using JAK inhibitors in myelofibrosis.

Ruben Mesa, MD, discusses the adverse events of ruxolitinib and fedratinib in myelofibrosis.

Ruben Mesa, MD, discusses theapproval of a second JAK inhibitor, fedratinib, to join ruxolitinib as a treatment option for patients with myelofibrosis.

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in treating patients with myelofibrosis.

Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the management of patients with myeloproliferative neoplasms.

Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses emerging treatment for myeloproliferative neoplasms (MPNs).

Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the treatment landscape for patients with myeloproliferative neoplasms (MPNs).

Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.

Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the significance of the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).

Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN). Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).